Cover Image
Market Research Report

Market Spotlight: Cachexia

Published by Datamonitor Healthcare Product code 923384
Published Content info 26 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Cachexia
Published: July 22, 2020 Content info: 26 Pages
Description

This Market Spotlight report covers the Cachexia market, comprising epidemiology, key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals.

Key Takeaways

Oxandrin, an orally active formulation of the anabolic steroid oxandrolone, is the only marketed drug available for cachexia. Industry-sponsored drugs in active clinical development for cachexia are spread evenly across Phase I and Phase II, with only one drug in Phase III.

Therapies in active clinical development for cachexia focus on targets such as ghrelin receptor, androgen receptors, and GDNF receptor alpha-like (GFRAL). These drugs are administered via the oral and subcutaneous routes.

The only high-impact upcoming event for drugs in the cachexia space is topline Phase II trial results for GSK2881078. The overall likelihood of approval of a Phase I metabolic-other asset is 10.2%, and the average probability a drug advances from Phase III is 70.6%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.0 years in the overall metabolic space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for cachexia have been in the early and midphases of development, with 66% of trials in Phase I-II, and only 34% in Phase III-IV.

The US has a substantial lead in the number of cachexia clinical trials globally, while the UK leads the major European markets. Clinical trial activity in the cachexia space is dominated by completed trials. Helsinn and Bristol Myers Squibb have the highest number of completed clinical trials for cachexia, with six trials each.

Helsinn leads industry sponsors with the highest overall number of clinical trials for cachexia, followed by Bristol Myers Squibb and GlaxoSmithKline.

Table of Contents
Product Code: DMKC0211594

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk groups
  • Diagnosis

TREATMENT

  • Treatment strategy
  • Drug classes

EPIDEMIOLOGY

  • Cancer cachexia prevalence
  • Prevalence of cachexia due to other main causes

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for cachexia in the US
  • Figure 2: Pipeline drugs for cachexia, by company
  • Figure 3: Pipeline drugs for cachexia, by drug type
  • Figure 4: Pipeline drugs for cachexia, by classification
  • Figure 5: Key upcoming events in cachexia
  • Figure 6: Probability of success in the cachexia pipeline
  • Figure 7: Clinical trials in cachexia
  • Figure 8: Top 10 drugs for clinical trials in cachexia
  • Figure 9: Top 10 companies for clinical trials in cachexia
  • Figure 10: Trial locations in cachexia
  • Figure 11: Cachexia trials status
  • Figure 12: Cachexia trials sponsors, by phase

LIST OF TABLES

  • Table 1: Drugs used for the treatment of cachexia
  • Table 2: Marketed drugs for cachexia
  • Table 3: Pipeline drugs for cachexia in the US
Back to Top